Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc

NNASDAQ:CURX
4.64
USD
-0.16
(-3.44%)
-7.57EPS
7.52MMarket Cap

Total Valuation

USD

As of June 30, 2026, Curanex Pharmaceuticals Inc carries a market capitalization of 7.52M, placing it among publicly traded companies globally. Its enterprise value stands at 4.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7.52M
Enterprise Value4.86M

Share Statistics

As of June 30, 2026, Curanex Pharmaceuticals Inc has 1.42M shares outstanding.

Shares Outstanding1.42M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio1.57
P/TBV Ratio1.57
P/FCF Ratio-0.61
P/OCF Ratio-0.61

Financial Position

As of June 30, 2026, Curanex Pharmaceuticals Inc maintains a current ratio of 45.95, meaning it holds 46.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.77, indicating elevated leverage, while an interest coverage ratio of -2,550.48 demonstrates limited ability to service its debt obligations.

Current Ratio45.95
Quick Ratio28.17
Debt / Equity5.77
Debt / EBITDA-0.03
Interest Coverage-2,550.48

Financial Efficiency

Over the twelve months ended June 30, 2026, Curanex Pharmaceuticals Inc posted a negative return on equity (ROE) of -411.10, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -357.22, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 6.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-411.10
Return on Assets (ROA)-357.22
Employee Count6.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Curanex Pharmaceuticals Inc's stock has declined approximately 54.26% over the past 52 weeks. The 50-day moving average sits at 4.97, while the 200-day moving average is 6.10.

52-Week Price Change-54.26%
50-Day Moving Average4.97
200-Day Moving Average6.10

Income Statement

USD

Over the twelve months ended June 30, 2026, Curanex Pharmaceuticals Inc generated - - in revenue and converted that into -10.47M in net income, yielding earnings per share of -7.57. EBITDA reached -10.43M, while operating income came in at -10.55M.

Operating Income-10.55M
Pretax Income-10.47M
Net Income-10.47M
EBITDA-10.43M
EBIT-10.55M
Earnings Per Share (EPS)-7.57

Balance Sheet

USD

As of June 30, 2026, Curanex Pharmaceuticals Inc holds 2.94M in cash and equivalents against 276,359.00 in total debt, resulting in a net debt position of -2.94M. Total book value stands at 4.79M, with working capital of 4.69M providing operational flexibility.

Cash & Cash Equivalents2.94M
Total Debt276,359.00
Net Debt-2.94M
Equity (Book Value)4.79M
Book Value Per Share3.38
Working Capital4.69M

Cash Flow

USD

Curanex Pharmaceuticals Inc produced -12.08M in operating cash flow over the twelve months ended June 30, 2026.

Operating Cash Flow-12.08M
Free Cash Flow-12.08M
FCF Per Share-8.73

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -164.65: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -198.19, meaning Curanex Pharmaceuticals Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-198.19
FCF Yield-164.65

Stock Splits

Curanex Pharmaceuticals Inc's most recent stock split took place on August 20, 2026 with a 20:1 split ratio.

Last Split Date8/20/2026
Split Ratio20:1

Scores

As of June 30, 2026, Curanex Pharmaceuticals Inc has an Altman Z-Score of 6.90, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.90